Vifor and Grünenthal ‘Named and Shamed’ for Breaking ABPI Code

Pharmaceutical companies Grünenthal and Vifor have been ‘named and shamed’ in numerous publications for breaking the Association of the British Pharmaceutical Industry’s (ABPI’s) Code of Practice. Grünenthal has been criticised for the way in which their team of health economic liaison managers drove interest in and awareness of their unlicensed pain reliever treatment, tapentadol. The

Continue Reading

Research Study Reveals Medication Warning Labels Require Overhaul

Numerous patients appear to overlook prescription drug warning labels with directions that are vital for safe and effective use, a research study by scientists at Michigan State University and a Kansas State University researcher have found. Patients, predominantly older ones, frequently ignore prescription advice labels partly due to the labels failing to capture their attention,

Continue Reading

Ferring Obtains Rights to Albireo’s Elobixibat

Ferring Pharmaceuticals announced yesterday that they have acquired the rights of Albireo’s elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). The arrangement provides Ferring with the rights to market the product internationally with the exception of Japan and a small number of Asian markets.  In April, Albireo,

Continue Reading

Drug Shortages Experienced in 80% of NHS Trusts

Eighty per cent of sixty National Health Service (NHS) trusts in England and Wales are facing “unacceptable” delays in locating drugs for patients, freedom of information requests by Labour MP Huw Irranca-Davies have exposed. About 70 to 80 drugs are still on the at risk list, including lifesaving drugs for serious diseases, such as cancer,

Continue Reading

Pfizer’s Xalkori Extends Lung Cancer Patient Survival

Pfizer yesterday revealed information that demonstrates that Xalkori considerably improved progression-free survival in previously-treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Xalkori (crizotinib) gained approval by the US Food and Drug Administration (FDA) in August 2011 for ALK-positive advanced NSCLC, but Pfizer points out that this latest clinical study, Profile

Continue Reading

NHS Public Satisfaction Rates Tumble

Public satisfaction regarding how the NHS functions across the UK dropped by 12% last year, to 58% from 70% in 2010, according to the most recent British Social Attitudes Survey. This is the largest decrease in one year from when the survey started in 1983, although it still remains the third highest documented level of

Continue Reading

Study Finds European Healthcare

In spite of the financial crisis, healthcare across Europe continues to improve, with consumer empowerment motivating advances in quality and access. However, the distribution of cancer drugs within the UK is still “deplorable,” states a new review, presented at the European Parliament in Brussels. The Netherlands appears first in the latest Euro Health Consumer Index

Continue Reading